TFS HealthScience earns an EcoVadis Gold Medal for 2026, scoring 84/100 and ranking in the top 3% of companies worldwide for sustainability.
Read More
TFS HealthScience supports benfovir AG’s early-phase trial of B-OT, a first-in-class transketolase inhibitor, in advanced prostate cancer.
TFS HealthScience and VERIGRAFT announce a partnership to advance P-TEV through pivotal Phase II/III trial in chronic venous insufficiency.
Our 2025 sustainability year in review shows major progress: −17% emissions, 99% renewable electricity, SBTi‑validated targets, and stronger ESG ratings.
TFS HealthScience, a leading global CRO, announces a noteworthy milestone in its commitment to environmental transparency and sustainability.
LUND, S.E., March 11, 2024 – TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), announces its expansion into the Asia Pacific (APAC) region, with the establishment of an…
Aims to enhance global trial recruitment and operations, reach underrepresented populations, help lower costs and increase speed to commercialization. Will leverage real-world data and evidence (RWD/RWE) and artificial intelligence (AI)-enabled…
LUND, Sweden (Nov. 6, 2023) – TFS HealthScience, a global contract research organization (CRO), announces its strategic investment in Medidata Detect, a comprehensive data surveillance and risk monitoring solution that…
LUND, S.E., 28 Jun 2023 – TFS HealthScience, a premier global contract research organization, is proud to announce that for the fourth consecutive year, it has received a Silver Rating…
LUND, S.E., 27 Mar 2023 – Today, TFS HealthScience, a global contract research organization, unveiled its new office in Lisbon, Portugal, due to growing customer demand. TFS Portugal will increase…